Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...

Regulation of the Cardiovascular System

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Old Problem, an Old Device, but Perhaps a New Indication? Intra-Aortic Balloon Counterpulsation for Intracoronary Thrombus.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

Same author

Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives.

International journal of molecular sciences·2024

Same author

Egr-1 functions as a master switch regulator of remote ischemic preconditioning-induced cardioprotection.

Basic research in cardiology·2019

Same author

Life after abciximab; what's next for intracoronary thrombus?

Journal of thrombosis and thrombolysis·2019

Same author

Molecular mechanisms of cardiac pathology in diabetes - Experimental insights.

Biochimica et biophysica acta. Molecular basis of disease·2017

Same author

High Rates of Self-Reported Depression in a Rapid Access Chest Pain Clinic (RACPC) Population From a Tertiary Metropolitan Hospital.

Heart, lung & circulation·2017

Search research articles

Related Experiment Video

Updated: Jul 5, 2026

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

DNAzymes and cardiovascular disease.

V L Benson¹, L M Khachigian, H C Lowe

¹ANZAC Research Institute, University of Sydney, Sydney, Australia.

British Journal of Pharmacology

|May 6, 2008

Summary

DNAzymes offer promising gene silencing for cardiovascular diseases, showing potential in treating myocardial ischemia and restenosis. Further research explores their clinical application and delivery methods.

Area of Science:

Biotechnology
Molecular Biology
Cardiovascular Research

Background:

Gene silencing is crucial for understanding gene function and developing cardiovascular disease therapies.
DNAzymes (catalytic DNA molecules) show therapeutic promise for myocardial ischemia reperfusion injury and in-stent restenosis in animal models.

Purpose of the Study:

To review recent advances in DNAzyme applications for cardiovascular disease.
To discuss DNAzyme design, mechanism, efficacy, and clinical delivery challenges.

Main Methods:

Review of construct and mechanism of DNAzymes, including design improvements.
Examination of DNAzyme-mediated gene inhibition in vitro (endothelial/smooth muscle cells) and in vivo (myocardial infarction, neointima formation) models.
Comparison of DNAzymes with other gene silencing tools.

More Related Videos

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Related Experiment Videos

Last Updated: Jul 5, 2026

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Main Results:

DNAzymes demonstrate potential in ameliorating cardiovascular conditions like myocardial ischemia and in-stent restenosis.
In vitro and in vivo studies show efficacy of DNAzyme-mediated gene inhibition in relevant cardiovascular models.
Comparative analysis highlights DNAzymes' potential alongside discussion of delivery challenges.

Conclusions:

DNAzymes represent a promising gene silencing strategy for cardiovascular diseases.
Recent advancements in DNAzyme design and demonstrated efficacy support their potential clinical utility.
Addressing delivery challenges is key for the successful clinical translation of DNAzyme therapeutics.